| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
repaglinide has not been evaluated in the literature showing its role of altering the activities of CYP3A.
|Not evaluated in the literature||anastrozole|
- Not evaluated in the literature: drugs implicated as inhibitors and inducers of CYP enzymes without reported clinical PK interaction studies.
Footnotes and References
|a.||likely to be a major inhibitor based on subjective evaluation (≥ 2-fold AUC increase or ≥ 50% decrease in clearance of in vivo CYP probe).|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.